313 related articles for article (PubMed ID: 22179302)
1. Vascular disease, Alzheimer's disease biomarkers and cognition in mild cognitive impairment: additive or synergetic effects?
Nordlund A; Göthlin M; Wallin A
Dement Geriatr Cogn Disord; 2011; 32(4):250-6. PubMed ID: 22179302
[TBL] [Abstract][Full Text] [Related]
2. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
3. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
[TBL] [Abstract][Full Text] [Related]
4. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
[TBL] [Abstract][Full Text] [Related]
5. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
Rolstad S; Berg AI; Bjerke M; Blennow K; Johansson B; Zetterberg H; Wallin A
J Alzheimers Dis; 2011; 26(1):135-42. PubMed ID: 21593572
[TBL] [Abstract][Full Text] [Related]
8. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition.
Tokuchi R; Hishikawa N; Kurata T; Sato K; Kono S; Yamashita T; Deguchi K; Abe K
J Neurol Sci; 2014 Nov; 346(1-2):288-92. PubMed ID: 25248955
[TBL] [Abstract][Full Text] [Related]
9. Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer's disease.
Nesteruk M; Nesteruk T; Styczyńska M; Mandecka M; Barczak A; Barcikowska M
Folia Neuropathol; 2016; 54(4):369-374. PubMed ID: 28139818
[TBL] [Abstract][Full Text] [Related]
10. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment.
Clerx L; van Rossum IA; Burns L; Knol DL; Scheltens P; Verhey F; Aalten P; Lapuerta P; van de Pol L; van Schijndel R; de Jong R; Barkhof F; Wolz R; Rueckert D; Bocchetta M; Tsolaki M; Nobili F; Wahlund LO; Minthon L; Frölich L; Hampel H; Soininen H; Visser PJ
Neurobiol Aging; 2013 Aug; 34(8):2003-13. PubMed ID: 23540941
[TBL] [Abstract][Full Text] [Related]
11. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
12. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
[TBL] [Abstract][Full Text] [Related]
13. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
14. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.
Damian M; Hausner L; Jekel K; Richter M; Froelich L; Almkvist O; Boada M; Bullock R; De Deyn PP; Frisoni GB; Hampel H; Jones RW; Kehoe P; Lenoir H; Minthon L; Olde Rikkert MG; Rodriguez G; Scheltens P; Soininen H; Spiru L; Touchon J; Tsolaki M; Vellas B; Verhey FR; Winblad B; Wahlund LO; Wilcock G; Visser PJ
Dement Geriatr Cogn Disord; 2013; 36(1-2):1-19. PubMed ID: 23651945
[TBL] [Abstract][Full Text] [Related]
15. Hippocampal complex atrophy in poststroke and mild cognitive impairment.
Selnes P; Grambaite R; Rincon M; Bjørnerud A; Gjerstad L; Hessen E; Auning E; Johansen K; Almdahl IS; Due-Tønnessen P; Vegge K; Bjelke B; Fladby T
J Cereb Blood Flow Metab; 2015 Nov; 35(11):1729-37. PubMed ID: 26036934
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.
Lueg G; Gross CC; Lohmann H; Johnen A; Kemmling A; Deppe M; Groger J; Minnerup J; Wiendl H; Meuth SG; Duning T
Neurobiol Aging; 2015 Jan; 36(1):81-9. PubMed ID: 25277040
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases.
Hessen E; Stav AL; Auning E; Selnes P; Blomsø L; Holmeide CE; Johansen KK; Eliassen CF; Reinvang I; Fladby T; Aarsland D
J Parkinsons Dis; 2016 Apr; 6(2):413-21. PubMed ID: 27061068
[TBL] [Abstract][Full Text] [Related]
19. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions.
Ossenkoppele R; van der Flier WM; Verfaillie SC; Vrenken H; Versteeg A; van Schijndel RA; Sikkes SA; Twisk J; Adriaanse SM; Zwan MD; Boellaard R; Windhorst AD; Barkhof F; Scheltens P; Lammertsma AA; van Berckel BN
Neurology; 2014 May; 82(20):1768-75. PubMed ID: 24748672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
